0001104659-16-163803.txt : 20161223
0001104659-16-163803.hdr.sgml : 20161223
20161223180209
ACCESSION NUMBER: 0001104659-16-163803
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161018
FILED AS OF DATE: 20161223
DATE AS OF CHANGE: 20161223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woiwode Thomas
CENTRAL INDEX KEY: 0001619294
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 162069509
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
3/A
1
a3a.xml
3/A
X0206
3/A
2016-10-18
2016-10-18
0
0001674416
CRISPR Therapeutics AG
CRSP
0001619294
Woiwode Thomas
C/O CRISPR THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
684014
I
See footnote
Common Shares
239648
I
See footnote
Series A-1 Preferred Shares
Common Shares
437247
I
See footnote
Series A-1 Preferred Shares
Common Shares
2754
I
See footnote
Series A-2 Preferred Shares
Common Shares
3100477
I
See footnote
Series A-2 Preferred Shares
Common Shares
19524
I
See footnote
Series A-3 Preferred Shares
Common Shares
2210417
I
See footnote
Series A-3 Preferred Shares
Common Shares
66490
I
See footnote
Series A-3 Preferred Shares
Common Shares
168224
I
See footnote
Series A-3 Preferred Shares
Common Shares
73704
I
See footnote
Series B Preferred Shares
Common Shares
231077
I
See footnote
Series B Preferred Shares
Common Shares
1454
I
See footnote
Series B Preferred Shares
Common Shares
173167
I
See footnote
Series B Preferred Shares
Common Shares
5210
I
See footnote
Series B Preferred Shares
Common Shares
13180
I
See footnote
Series B Preferred Shares
Common Shares
5774
I
See footnote
Each of the Reporting Person and Bradley Bolzon are managing members of Versant Venture Management, LLC. One-half of these shares were issued to the Reporting Person and one-half of these shares were issued to Mr. Bolzon, in each case, as compensation for service on the Issuer's board of directors. Pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
These securities are convertible on a one-for-one basis at any time into the Issuer's Common Shares at the holder's election and automatically upon the closing of the Issuer's initial public offering into the number of Common Shares shown in column 3 above. These securities do not have an expiration date.
These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
This amendment is being filed solely to correct the reporting of ownership of certain shares of Common Stock reported in Table I that are held for the benefit of Versant Venture Management, LLC. See Footnote 1.
Thomas Woiwode
2016-12-23